Ascensia Diabetes Care

What Ascensia Diabetes Care does

Ascensia Diabetes Care is a global diabetes care company headquartered in Basel, Switzerland, and operating as a wholly owned subsidiary of PHC Holdings Corporation (PHC Group). Founded in 2016 and tracing its heritage to over 80 years of blood glucose monitoring innovation through predecessor companies, Ascensia manufactures and distributes the CONTOUR portfolio of electrochemical blood glucose meters and compatible test strips (CONTOUR NEXT, CONTOUR NEXT ONE, CONTOUR CARE, CONTOUR PLUS, CONTOUR PLUS ELITE), supported by MICROLET lancing devices. Its product platform is differentiated by proprietary features including Second-Chance sampling (allowing 30-second reapplication of blood to reduce strip waste), smartLIGHT color-coded range indicators, and Bluetooth connectivity to the CONTOUR Diabetes App, which provides pattern detection, test reminders, and clinician report sharing, with the Glucocontro.online cloud platform enabling healthcare-provider remote data access.

The company generates revenue primarily through hardware sales of meters combined with recurring consumable strip purchases, augmented by digital health software and services tied to the CONTOUR ecosystem. Ascensia sells directly via over 70 country-specific websites and e-commerce storefronts, and indirectly through a global network of pharmacy chains, retailers, and regional authorized distributors across Africa, Asia Pacific, Europe, Latin America, the Middle East, and North America. Historically, Ascensia also served as the global commercial distribution partner for Senseonics' Eversense CGM products, including the 365-day implantable Eversense 365 (FDA-cleared September 2024); this partnership is winding down as Senseonics brings commercialization in-house in 2025-2026. Ascensia holds EU MDR, IVDR, and RED regulatory clearances for its product portfolio, is GDPR-compliant for cloud-stored patient data, and is identified as a principal CGM patent assignee alongside Abbott, Medtronic, Dexcom, and Roche. Leadership transitioned in April 2026 with Peter Bodlund succeeding Koichiro Sato as President and CEO.

Name

Ascensia Diabetes Care

Legal name

Ascensia Diabetes Care Holdings AG

Website

https://ascensia.com

Company type

Private

Founded year

1940

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ascensia Diabetes Care is a global, Switzerland-based subsidiary of PHC Group that manufactures and distributes the CONTOUR portfolio of blood glucose meters and consumable test strips, plus the CONTOUR Diabetes App and Glucocontro.online HCP cloud platform, serving people with diabetes across more than 70 countries.

Ownership category

akta.pro rank

Product category

Blood Glucose Monitoring Devices

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)

akta.pro secondary industries

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Blood glucose monitoring
• Diabetes management devices
• Continuous glucose monitoring
• Glucose test strips
• Diabetes self-management

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices30 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Blood Glucose Monitoring Hardware: Sale of CONTOUR portfolio blood glucose meters and compatible test strips. The core product line includes CONTOUR NEXT, CONTOUR CARE, CONTOUR PLUS ELITE, and related test strips, generating recurring revenue through consumable strip purchases alongside durable meter devices.
2. Digital Health Software & Services: Revenue generated from the CONTOUR Diabetes App (free to patients, supported by device ecosystem lock-in) and Glucocontro.online cloud platform enabling remote healthcare provider data access, adding recurring software value to the hardware ecosystem.
3. Distribution Revenue (Senseonics Eversense): Ascensia previously received revenue share from Senseonics for global commercialization of Eversense CGM products. Senseonics has transitioned commercialization in-house starting 2025, reducing this revenue stream for Ascensia.
4. Lancing Devices and Accessories: Sale of MICROLET NEXT and SINGLE-LET NEXT lancing devices and lancets, complementing the core blood glucose monitoring portfolio.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Ascensia Diabetes Care manufactures and sells the CONTOUR portfolio of electrochemical blood glucose monitoring systems — including CONTOUR NEXT, CONTOUR CARE, CONTOUR PLUS ELITE meters and their compatible test strips — paired with proprietary Second-Chance® sampling and smartLIGHT® indicators. The company complements its hardware with the Bluetooth-enabled CONTOUR Diabetes App, the Glucocontro.online cloud platform for remote data sharing with healthcare professionals, MICROLET lancing devices, and previously served as global commercial distributor for Senseonics' Eversense 365 implantable CGM. Products are sold in 70+ countries through company e-commerce sites, pharmacies, and authorized distributors to people with diabetes (Type 1, Type 2, gestational) and their healthcare providers.

Product overview

Ascensia Diabetes Care offers a comprehensive diabetes management portfolio centered on the CONTOUR brand of blood glucose monitoring systems. The core portfolio includes CONTOUR NEXT and CONTOUR CARE blood glucose meters, which are paired with compatible test strips. The digital ecosystem comprises the CONTOUR Diabetes App for smartphone-based tracking and the Glucocontro.online platform for remote healthcare professional data sharing. Accessories include MICROLET NEXT lancing devices. The product line emphasizes accuracy, Second-Chance sampling technology for strip savings, and smartLIGHT color-coded target range indicators. The portfolio serves both Type 1 and Type 2 diabetes patients across global markets.

Differentiator

Problem solved

Functional benefit

Brands

• CONTOUR: World-renowned portfolio of blood glucose monitoring systems combining advanced technology with user-friendly functionality.
• CONTOUR NEXT
• CONTOUR CARE
• CONTOUR PLUS ELITE
• CONTOUR PLUS
• MICROLET
• CONTOUR Diabetes App
• Glucocontro.online

Products and services

• CONTOUR NEXT Blood Glucose Monitoring System Advanced blood glucose monitoring system featuring high accuracy, Second-Chance® sampling technology to save test strips, and smartLIGHT® color-coded target range indicators. Designed for people with diabetes who self-monitor blood glucose at home.
• CONTOUR NEXT ONE Blood Glucose Meter Connected blood glucose meter with Bluetooth connectivity that automatically syncs readings with the CONTOUR Diabetes App for data transfer, tracking, pattern detection, and remote sharing with healthcare providers.
• CONTOUR CARE Blood Glucose Monitoring System Blood glucose monitoring system designed for ease of use with Second-Chance® sampling that allows users 30 seconds to apply more blood to the same strip if the first sample was insufficient, reducing strip waste.
• CONTOUR NEXT Test Strips Highly accurate electrochemical test strips for use with CONTOUR NEXT and CONTOUR NEXT ONE meters, incorporating Second-Chance® Sampling technology to reduce strip waste. Sold as a recurring consumable alongside the meter hardware.
• CONTOUR CARE Test Strips Test strips designed for the CONTOUR CARE meter with Second-Chance® sampling that allows 30 seconds to reapply blood to the same strip. Sold as a recurring consumable.
• CONTOUR Diabetes App Free smartphone application for diabetes self-management that pairs with CONTOUR connected meters via Bluetooth, providing automatic reading synchronization, test reminders, pattern detection, meal and medication logging, and report sharing with healthcare providers.
• Glucocontro.online Cloud-based, GDPR-compliant digital health platform that enables healthcare professionals to remotely access and monitor blood glucose data from patients using CONTOUR connected meters and the CONTOUR Diabetes App. Patient data is stored in cloud data centers in France and Germany.
• MICROLET NEXT Lancing Device Lancing device for capillary blood sampling used in blood glucose testing, designed for ease of use with single-use lancets. Part of the MICROLET accessory line that complements the CONTOUR meter portfolio.
• SINGLE-LET NEXT Single-use lancing device for blood glucose testing, designed for one-time use to support safe and hygienic capillary blood sampling.
• Eversense 365 Continuous Glucose Monitor (distribution) 365-day implantable continuous glucose monitoring system co-commercialized globally by Ascensia Diabetes Care in partnership with Senseonics Holdings. The system uses a long-term implantable sensor paired with a removable smart transmitter, distinguishing it from standard 10–14 day CGM sensors.

Quantifiable outcome

• Ascensia is identified as a leading CGM patent filer alongside Abbott, Medtronic, and Dexcom, with significant filings in factory calibration and sensor drift correction
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Senseonics Holdings, Inc.coreChannel Partner/ Reseller/ Distributor · 1 January 2025Ascensia Diabetes Care served as the global commercial distribution partner for Senseonics' Eversense CGM products, including the Eversense 365 (365-day implantable CGM). Under this partnership, Ascensia managed commercialization including sales, marketing, and distribution. Senseonics announced plans to transition commercialization back in-house starting January 1, 2025 for the U.S. and 2026 for Europe, as part of a strategic move to control their commercial destiny and enable faster pivots and adjustments. The transition included Senseonics recapturing revenue share and acquiring key sales staff from Ascensia, supported by a new debt facility of up to $100 million from Hercules Capital.
• Regional Authorized Distributors (Africa, Middle East, Asia Pacific)minorChannel Partner/ Reseller/ DistributorAscensia operates through a network of authorized regional distributors in multiple geographies. Examples include: Pharmaco in South Africa, Akigroup in UAE, Warba Medical Supplies in Kuwait, Batterjee Holding in Saudi Arabia, Dongguk Life Sciences in Korea, and Allium UPI in Baltic states. These distributors handle local market sales, distribution, and customer service on behalf of Ascensia.
• PHC Holdings Corporation (Parent Company)coreStrategic or Co-development PartnerAscensia Diabetes Care is a subsidiary of PHC Holdings Corporation (PHC Group), a Japan-based global healthcare company. PHC Group's mid-term plan (initiated November 2022) integrates ESG principles and focuses on 11 key issues across environmental, social, and governance areas. PHC Group reported Q3 2025 revenue of 269.3 billion JPY and has a market cap of approximately $859 million. Ascensia's CEO transition (Peter Bodlund succeeding Koichiro Sato effective April 1, 2026) reflects alignment with PHC Group's long-term strategic direction.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Trividia Health: Trividia markets the TRUE METRIX line of BGM meters and strips. It is a smaller but direct BGM competitor focused on cost-sensitive segments where Ascensia's CONTOUR also competes.
• AgaMatrix: AgaMatrix manufactures Bluetooth-enabled blood glucose meters and test strips (e.g., AgaMatrix WaveSense/Jazz). It competes with Ascensia in the connected BGM niche with smaller scale.
• Ypsomed: Ypsomed's mylife Diabetescare line includes BGM systems alongside insulin pumps and pen needles. It overlaps with Ascensia's diabetes care portfolio, particularly in European markets.

Direct peers

• Roche Diabetes Care: Roche's diabetes division markets the Accu-Chek portfolio of blood glucose meters and test strips — the closest direct BGM competitor to Ascensia's CONTOUR brand, serving the same patient and HCP segments globally.
• LifeScan (Platinum Equity): LifeScan markets the OneTouch portfolio of blood glucose monitoring systems and strips. It is a direct BGM peer acquired by Platinum Equity in 2018 for ~$2.1B, indicating comparable scale and strategic positioning to Ascensia.
• Abbott Diabetes Care: Abbott is both a BGM competitor (FreeStyle meters/strips) and the global CGM leader (FreeStyle Libre). It is the principal disruptive force in diabetes monitoring and competes directly with Ascensia across its core and adjacent segments.
• Dexcom: Dexcom is the leading standalone continuous glucose monitor manufacturer. As CGM penetration cannibalizes BGM volume, Dexcom is the structural competitor whose growth directly pressures Ascensia's strip-based business.
• Medtronic Diabetes: Medtronic's Diabetes division offers integrated insulin pumps and CGM (Guardian). It competes with Ascensia in connected diabetes management and is one of the five principal CGM patent assignees alongside Ascensia.

Regional players

• Sinocare: Sinocare is a leading Chinese diabetes device manufacturer (BGM meters, strips, and emerging CGM). It competes with Ascensia primarily in China and emerging Asia-Pacific markets where Ascensia also operates.

Others

• Senseonics Holdings: Senseonics developed the Eversense implantable CGM that Ascensia distributed until commercialization transitioned back in-house in 2025-2026. It is a former strategic partner and now a competing CGM route-to-market in the same patients Ascensia serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ContourDiabetes
• Facebookfacebook.com/ContourDiabetes
• LinkedInlinkedin.com/company/ascensia-diabetes-care
• Instagraminstagram.com/contourdiabetes
• Xx.com/contourascensia

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascensia Diabetes Care